Literature DB >> 8779124

British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.

G J Gibson1, R J Prescott, M F Muers, W G Middleton, D N Mitchell, C K Connolly, B D Harrison.   

Abstract

BACKGROUND: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven.
METHODS: Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study.
RESULTS: One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals.
CONCLUSIONS: After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8779124      PMCID: PMC1090632          DOI: 10.1136/thx.51.3.238

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  13 in total

1.  Airflow limitation in sarcoidosis--a study of pulmonary function in 107 patients with newly diagnosed disease.

Authors:  B D Harrison; J M Shaylor; T C Stokes; A R Wilkes
Journal:  Respir Med       Date:  1991-01       Impact factor: 3.415

2.  Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study.

Authors:  M H Zaki; H A Lyons; L Leilop; C T Huang
Journal:  N Y State J Med       Date:  1987-09

3.  A controlled trial of prednisone treatment of sarcoidosis.

Authors:  H L Israel; D W Fouts; R A Beggs
Journal:  Am Rev Respir Dis       Date:  1973-04

4.  A ten-year study of corticosteroid treatment of pulmonary sarcoidosis.

Authors:  C J Johns; J B Zachary; W C Ball
Journal:  Johns Hopkins Med J       Date:  1974-05

5.  Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy.

Authors:  R L Young; L E Harkleroad; R E Lordon; J G Weg
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

6.  The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study.

Authors:  H Eule; A Weinecke; I Roth; H Wuthe
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

7.  The present status of treatment of pulmonary sarcoidosis: a house divided.

Authors:  R A DeRemee
Journal:  Chest       Date:  1977-03       Impact factor: 9.410

8.  Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy.

Authors:  L E Harkleroad; R L Young; P J Savage; D W Jenkins; R E Lordon
Journal:  Chest       Date:  1982-07       Impact factor: 9.410

9.  Sarcoidosis: a disorder commoner in non-smokers?

Authors:  J G Douglas; W G Middleton; J Gaddie; G R Petrie; Y F Choo-Kang; R J Prescott; G K Crompton
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

10.  Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease.

Authors:  O Selroos; T L Sellergren
Journal:  Scand J Respir Dis       Date:  1979-08
View more
  46 in total

Review 1.  A clinical approach to the use of methotrexate for sarcoidosis.

Authors:  R P Baughman; E E Lower
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 3.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

Review 4.  Practical issues and challenges in the diagnosis and treatment of pulmonary sarcoidosis.

Authors:  Surinder K Jindal
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Patient reported outcome measures (PROMs) in sarcoidosis.

Authors:  Rikke Flor Thunold; Anders Løkke; Adam Langballe Cohen; Hilberg Ole; Elisabeth Bendstrup
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

6.  Glucocorticosteroids and pulmonary sarcoidosis.

Authors:  O Selroos
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

7.  Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.

Authors:  W P Drake; B W Richmond; K Oswald-Richter; C Yu; J M Isom; J A Worrell; G R Shipley
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-11-25       Impact factor: 0.670

8.  Sarcoidosis Presenting as a Proximal Phalangeal Bony Swelling-a Case and Review of the Literature.

Authors:  Andrew D Duckworth; Adam T Hill; Ian Beggs; James T Patton; Donald M Salter; Daniel E Porter
Journal:  Hand (N Y)       Date:  2009-06-11

Review 9.  New molecular targets for the treatment of sarcoidosis.

Authors:  Jared Chiarchiaro; Bill B Chen; Kevin F Gibson
Journal:  Curr Opin Pulm Med       Date:  2016-09       Impact factor: 3.155

10.  Management strategies for pulmonary sarcoidosis.

Authors:  Robina Kate Coker
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.